rs121913600
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The NM_000530.8(MPZ):c.308G>A(p.Gly103Glu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G103W) has been classified as Uncertain significance.
Frequency
Consequence
NM_000530.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MPZ | NM_000530.8 | c.308G>A | p.Gly103Glu | missense_variant | Exon 3 of 6 | ENST00000533357.5 | NP_000521.2 | |
MPZ | NM_001315491.2 | c.308G>A | p.Gly103Glu | missense_variant | Exon 3 of 6 | NP_001302420.1 | ||
MPZ | XM_017001321.3 | c.338G>A | p.Gly113Glu | missense_variant | Exon 3 of 6 | XP_016856810.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 29
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 29
ClinVar
Submissions by phenotype
Charcot-Marie-Tooth disease type 1B Pathogenic:1
- -
not provided Pathogenic:1
Reported previously in two sisters with severe CMT1 neuropathy; this variant was inherited from a mother who was mosaic for the G103E variant (Fabrizi et al., 2001); Published functional studies demonstrate that the unfolded protein response (UPR) and endoplasmic reticulum (ER) retention was significantly increased in the G103E variant when compared to wild type (Bai et al., 2018); Not observed at significant frequency in large population cohorts (gnomAD); Missense variants in this gene are often considered pathogenic (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26310628, 20461396, 20456450, 28063088, 11445635, 29687021, 30076350, 24077912, 28902413) -
Charcot-Marie-Tooth disease, type I Pathogenic:1
This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 103 of the MPZ protein (p.Gly103Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease (PMID: 11445635; internal data). In at least one individual the variant was observed to be de novo. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MPZ variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 11,906 individuals referred to our laboratory for MPZ testing. ClinVar contains an entry for this variant (Variation ID: 14187). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MPZ protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects MPZ function (PMID: 29687021). This variant disrupts the p.Gly103 amino acid residue in MPZ. Other variant(s) that disrupt this residue have been observed in individuals with MPZ-related conditions (PMID: 20456450), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. -
Inborn genetic diseases Uncertain:1
The p.G103E variant (also known as c.308G>A), located in coding exon 3 of the MPZ gene, results from a G to A substitution at nucleotide position 308. The glycine at codon 103 is replaced by glutamic acid, an amino acid with similar properties. This variant was detected in two siblings with Charcot-Marie-Tooth disease type 1 (CMT1), whose mother was also mosaic for the variant (Fabrizi GM et al. Neurology, 2001 Jul;57:101-5). This variant was also detected in an individual with Charcot-Marie-Tooth disease, type 1B (CMT1B); however, clinical details were limited (Sanmaneechai O et al. Brain, 2015 Nov;138:3180-92). Functional studies revealed this alteration led to abnormal accumulation in the ER and activation of the UPR (Bai Y et al. Ann Clin Transl Neurol, 2018 Apr;5:445-455). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at